Selective serotonin reuptake inhibitors in pregnancy

Current Medicinal Chemistry

Volumn 19, Issue 27, 2012, Pages 4554-4561

  Bellissima, V ^a   Ververs, T F F ^b   Visser, G H A ^b   Gazzolo, D ^a,c  

^a C Arrigo Children's Hospital   (Italy)

^b Utrecht Medical Center   (Netherlands)

^c University Hospital   (Italy)

Author keywords

Depression; Fetus; Newborn; Pregnancy; SSRI; Teratogenic effect

Indexed keywords

11B HYDROXYSTEROID DEHYDROGENASE; CITALOPRAM; ENZYME; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HYDROCORTISONE; MESSENGER RNA; NORADRENALIN; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT;

ARTICLE; CHILD DEVELOPMENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; FETUS DEVELOPMENT; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOKINETICS; PRACTICE GUIDELINE; PREGNANCY; PRENATAL EXPOSURE; PRENATAL STRESS; PUERPERAL DEPRESSION; VOLUME OF DISTRIBUTION; BEHAVIOR; CONGENITAL MALFORMATION; DEPRESSION; FETOMATERNAL TRANSFUSION; REVIEW; RISK ASSESSMENT;

ABNORMALITIES, DRUG-INDUCED; ANTIDEPRESSIVE AGENTS; BEHAVIORAL SYMPTOMS; DEPRESSIVE DISORDER; FEMALE; HUMANS; MATERNAL-FETAL EXCHANGE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS;

EID: 84875254989     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803306349     Document Type: Article

References (111)

1. Blehar, M.C. Women's mental health research: the emergence of a biomedical field. Annu. Rev. Clin. Psychol. 2006, 2, 135-60.
2. Bennett, H.A.; Einarson, A.; Taddio, A; Koren, G.; Einarson, T.R. Prevalence of depression during pregnancy: systematic review. Obstet. Gynecol. 2004, 103, 698-709.
3. Lattimore, K.A.; Donn, S. M.; Kaciroti, N.; Kemper, A.R.; Neal Jr, C.R.; Vazquez, D. Selective Serotonin Reuptake Inhibitor (SSRI) Use during Pregnancy and Effects on the Fetus and Newborn: A Meta-Analysis. J. Perinatol. 2005, 25, 595-604.
4. Austin, M.P.; Kildea, S.; Sullivan, E. Maternal mortality and psychiatric morbidity in the perinatal period: challenges and opportunities for prevention in the Australian setting. Med J Aust., 2007, 186, 364-367.
5. Austin, M.P. To treat or not to treat: maternal depression. SSRI use in pregnancy and adverse neonatal effects. Psychol Med. 2006, 36, 1663-1670.
6. Bonari, L.; Pinton, N.; Ahn, E.; Einarson, A.; Steiner, M.; Koren, G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry. 2004, 49, 726-35.
7. Kinsella, M.T.; Monk, C. Impact of maternal stress, depression and anxiety on fetal neurobehavioral development. Clin Obstet Gynecol. 2009, 52, 425-440.
8. Wadhwa, P.D. Psychoneuroendocrine processes in human pregnancy influence fetal development and health. Psychoneuroendocrinology. 2005, 30, 724-43.
9. Strug, L.J.; Suresh, R.; Fyer, A.J.; Talati, A.; Adams, P.B.; Li, W.; Hodge, S.E.; Gilliam, T.C.; Weissman, M.M. Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR). Mol Psychiatry. 2010, 15, 166-76.
10. Gotlib, I.H.; Joormann, J.; Minor, K.L.; Hallmayer, J. HPA axis reactivity: a mechanism underlying the associations among 5-HTTLPR, stress, and depression. Biol Psychiatry. 2008, 63, 847-51.
11. Ressler, K.J.; Nemeroff, C.B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety. 2000, 12, 2-19.
12. Gillespie, C.F.; Nemeroff, C.B. Hypercortisolemia and depression. Psychosom Med. 2005, 67, 26-8.
13. Field, T.; Diego, M.A.; Hernandez-Reif, M.; Figueiredo, B.; Ascencio, A.; Schanberg, S.; Kuhn, C. Prenatal dysthmya versus major depression effects on maternal cortisol and fetal growth. Depress Anxiety. 2008, 25, E11-6.
14. Tekes, K.; Szegi, P.; Laufer, R.; Hantos, M.; Csaba, G. Effect of perinatal stress on the biogenic amine neurotransmitter level of the adult rat's brain. Int J Dev Neurosci. 2011, 29, 171-5.
15. Field, T.; Diego, M.; Hernandez-Reif, M.; Schanberg, S.; Kuhn, C.;Yando, R.;Bendell, D. Pregnancy anxiety and comorbid depression and anger: effects on the fetus and neonate. Depress Anxiety. 2003, 17, 140-51.
16. Rayen, I.; van den Hove, D.L.; Prickaerts, J.; Steinbusch, H.W.; Pawluski, J.L. Fluoxetine during development reverses the effects of perinatal stress on depressive-like behavior and hippocampal neurogenesis in adolescence. PLoS One, 2011, 6, e24003.
17. Silberg, J.L.; Maes, H.; Eaves, L.J. Genetic and environmental influences on the transmission of parental depression to children's depression and conduct disturbance: an extended Children of Twins study. J Child Psychol Psychiatry. 2010, 51, 734-44.
18. Simon, G.E.; Cunningham, M.L.; Davis, R.L. Outcomes of prenatal antidepressant exposure. Am J Psychiatry, 2002. 159, 2055-61.
19. Monk, C.; Sloan, R.P.; Myers, M.M.; Ellman, L.; Werner, E.; Jeon, J.; Tager, F.; Fifer, W.P. Fetal heart rate reactivity differs by women's psychiatric status: an early marker for developmental risk? J Am Acad Child Adolesc Psychiatry. 2004, 43, 283-90.
20. de Weerth, C.; van Hees, Y.; Buitelaar, J.K. Prenatal maternal cortisol levels and infant behavior during the first 5 months. Early Hum Dev. 2003, 74, 139-51.
21. Burt, V.K.; Quezada, V. Mood disorders in women: focus on reproductive psychiatry in the 21st century-Motherisk update 2008. Can J Clin Pharmacol. 2009, 16, e6-e14.
22. Prasad, P.D.; Leibach, F.H.; Mahesh, V.B.; Ganapathy, V. Human placenta as a target organ for cocaine action: interaction of cocaine with the placental serotonin transporter. Placenta. 1994, 15, 267-78.
23. Ramamoorthy, J.D.; Ramamoorthy, S.; Leibach, F.H.; Ganapathy, V. Human placental monoamine transporters as targets for amphetamines. Am J Obstet Gynecol. 1995, 173, 1782-7.
24. Kim, H.; Lim, S.W.; Kim, S.; Kim, J.W.; Chang, Y.H.; Carroll, B.J.; Kim, D.K. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA. 2006, 296, 1609-18.
25. Kittler, K.; Lau, T.; Schloss, P. Antagonists and substrates differentially regulate serotonin transporter cell surface expression in serotonergic neurons. Eur J Pharmacol. 2010, 10, 63-7.
26. Bottalico, B.; Larsson, I; Brodszki, J.; Hernandez-Andrade, E.; Casslén, B.; Marsál, K.; Hansson, S.R. Norepinephrine transporter (NET), serotonin transporter (SERT), vesicular monoamine transporter (VMAT2) and organic cation transporters (OCT1, 2 and EMT) in human placenta from preeclamptic and normotensive pregnancies. Placenta. 2004, 25, 518-29.
27. Bzoskie, L.; Yen, J.; Tseng, Y.T.; Blount, L.; Kashiwai, K.; Padbury, J.F. Human placental norepinephrine transporter mRNA: expression and correlation with fetal condition at birth. Placenta. 1997, 18, 205-10.
28. Welberg, L.A; Seckl, J.R.; Holmes, M.C. Inhibition of 11betahydroxysteroid dehydrogenase, the foeto-placental barrier to maternal glucocorticoids, permanently programs amygdala GR mRNA expression and anxiety-like behaviour in the offspring. Eur J Neurosci. 2000, 12, 1047-54.
29. van Beek, J.P.; Guan, H.; Julan, L.; Yang, K. Glucocorticoids stimulate the expression of 11beta-hydroxysteroid dehydrogenase type 2 in cultured human placental trophoblast cells. J Clin Endocrinol Metab., 2004. 89, 5614-21.
30. Sarkar, S.; Tsai, S.W.; Nguyen, T.T.; Plevyak, M.; Padbury, J.F.; Rubin, L.P. Inhibition of placental 11beta-hydroxysteroid dehydrogenase type 2 by catecholamines via alpha-adrenergic signaling. Am J Physiol Regul Integr Comp Physiol. 2001, 281, R1966-74.
31. Levinson-Castiel, R.; Merlob, P.; Linder, N.; Sirota, L.; Klinger, G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006, 160, 173-6.
32. El Marroun, H.; Jaddoe, V. W. V.; Hudziak, J. J.; Roza, S. J.; Steegers, E. A. P.; Hofman, A.; Verhulst, F.C.; White, T.J. H.; Stricker, B. H. C.; Tiemeier, H. Maternal Use of Selective Serotonin Reuptake Inhibitors, Fetal Growth, and Risk of Adverse Birth Outcomes. Arch Gen Psychiatry. 2012, PMID: 22393202.
33. Oberlander, T.F.; Grunau, R.; Mayes, L.; Riggs, W.; Rurak, D.; Papsdorf, M.; Misri, S.; Weinberg, J. Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure. Early Hum Dev. 2008, 84, 689-97.
34. Mulder EJ, Ververs FF, de Heus R, Visser GH. Selective serotonin reuptake inhibitors affect neurobehavioral development in the human fetus. Neuropsychopharmacology. 2011, 36, 1961-71
35. Chambers, C.D.; Hernandez-Diaz, S.; Van Marter, L.J.; Werler, M.M.; Louik, C.; Jones, K.L.; Mitchell, A.A. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006, 354, 579-87.
36. Kalra, S.; Born. L.; Sarkar, M.; Einarson, A. The safety of antidepressant use in pregnancy. Expert Opin Drug Saf. 2005, 4, 273-84.
37. Andrade, S.E., Raebel, M.A.; Brown, J.; Lane, K.; Livingston, J.; Boudreau, D.; Rolnick, S.J.; Roblin, D.; Smith, D.H.; Willy, M.E.; Staffa, J.A.; Platt, R. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol. 2008, 198, e1-5.
38. Rampono, J.; Simmer, K.; Ilett, K.F.; Hackett, L.P.; Doherty, D.A.; Elliot, R.; Kok, C.H.; Coenen, A.; Forman, T. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry. 2009, 42, 95-100.
39. Kinney, H.C.; Belliveau, R.A.; Trachtenberg, F.L.; Rava, L.A.; Paterson, D.S. The development of the medullary serotonergic system in early human life. Autonomic Neuroscience: Basic and Clinical. 2007, 132, 81-102.
40. Maciag, D.; Simpson, K.L.; Coppinger, D.; Lu, Y.; Wang, Y.; Lin, R.C.; Paul, I.A. Neonatal antidepressant exposure has lasting effects on behaviour and serotonine circuitry. Neuropsychopharmacology. 2006, 31, 47-57.
41. Lucki, I. The spectrum of behaviors influenced by serotonin. Biol. Psychiatry. 1998, 44: 151-162.
42. Lauder, J.M. Neurotransmitters as growth regulatory signals: role of receptors and second messengers. Trends Neurosci. 1993, 16, 233-40.
43. Anderson, I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability. J. Affect. Disord. 2000, 58, 19-36.
44. Hiemke, C.; Hartter, S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000, 85, 11-28.
45. Nemeroff, C.B.; DeVane, C.L.; Pollock, B.G. Newer antidepressants and the cytochrome P450 system. Am. J. Psychiatry. 1996, 153, 311-320.
46. Grasmäder, K.; Verwohlt, P.L.; Rietschel, M.; Dragicevic, A.; Müller, M.; Hiemke, C.; Freymann, N.; Zobel, A.; Maier, W.; Rao, M.L. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur. J. Clin. Pharmacol. 2004, 60, 329-36.
47. Ververs, F.F, Voorbij, H.A.; Zwarts, P.; Belitser, S.V.; Egberts, T.C.; Visser, G.H.; Schobben, A.F. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clin Pharmacokinet. 2009, 48, 677-83.
48. Anderson, G.D. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clinical. Pharmacokinetics. 2005, 44, 989-1008.
49. Preskorn, S.H. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin. Pharmacokinet. 1997, 32, 1-21.
50. Heikkinen, T.; Ekblad, U.; Palo, P.; Laine, K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther. 2003, 73, 330-7.
51. Alwan, S.; Reefhuis, J.; Rasmussen, S.A. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007, 356, 2684-92.
52. Nijenhuis, C.M.; ter Horst, P.G.J.; de Jong-van den Berg, L. T. W.; Wilffert, B. Disturbed development of the enteric nervous system after in utero exposure of selective serotonine re-uptake inhibitors and tricyclic antidepressants. Br J Clin Pharmacol. 2011, 73:1, 16-26, 126-134.
53. van Harten, J. Overview of the pharmacokinetics of fluvoxamine. Clin. Pharmacokinet. 1995, 29, 1-9.
54. Kristensen, J.H.; Hackett, L.P.; Kohan, R.; Paech, M.; Ilett, K.F. The amount of fluvoxamine in milk is unlikely to be a cause of adverse effects in breastfed infants. J Hum Lact. 2002, 18, 139-43.
55. Bourin, M.; Chue, P.; Guillon, Y. Paroxetine: a review. CNS. Drug. Rev. 2001, 7, 25-47.
56. GlaxoSmithKline. EPIP083 (preliminary report) epidemiology study: preliminary report on bupropion in pregnancy and the occurrence of cardiovascular and major congenital malformations [online]. Available from URL: http://ctr.gsk.co.uk/summary/bupropion/studylist.asp.
57. DeVane, C.L.; Liston, H.L.; Markowitz, J.S. Clinical pharmacokinetics of sertraline. Clin. Pharmacokinet. 2002, 41, 1247-66.
58. Sit, D.; Perel, J.M.; Wisniewski, S.R.; Helsel, J.C.; Luther, J.F.; Wisner, K.L. Mother-infant antidepressant concentrations, maternal depression, and perinatal events. J Clin Psychiatry. 2011, 72, 994-1001
59. Louik, C.; Lin, A.E.; Werler, M.M. First-trimester use of selective serotoninreuptake inhibitors and the risk of birth defects. N Engl J Med. 2007, 356, 2675-83.
60. Bezchlibnyk-Butler, K.; Aleksic, I.; Kennedy, S.H. Citalopram-a review of pharmacological and clinical effects. J Psychiatry Neurosci. 2000, 25, 241-54.
61. Pedersen, L.H.; Henriksen, T.B.; Vestergaard, M. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ. 2009, 339, b3569.
62. Rao, N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007, 46, 281-90.
63. Rampono, J.; Hackett, L.P.; Kristensen, J.H.; Kohan, R.; Page-Sharp, M.; Ilett, K.F. Transfer of escitalopram and its metabolite demethylescitalopram into breastmilk. Br J Clin Pharmacol. 2006, 62, 316-22.
64. Costa, L.G.; Steardo L.; Cuomo, V. Structural effects and neurofunctional sequelae of developmental exposure to psychotherapeutic drugs: experimental and clinical aspects. Pharmacol Rev. 2004, 56, 103-147.
65. Noorlander, C.W.; Ververs, F.F.; Nikkels, P.G.; van Echteld, C.J.; Visser, G.H.; Smidt, M.P. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS One. 2008, 23, e2782.
66. Moses-Kolko, E.L.; Bogen, D.; Perel, J.; Bregar, A.; Uhl, K.; Levin, B.; Wisner, K.L. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005, 293, 2372-83.
67. Louik, C.; Lin, A.E.; Werler, M.M.; Hernández-Díaz, S.; Mitchell, A.A. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007, 356, 2675-83.
68. Hemels, M.E.; Einarson, A.; Koren, G. et al. Antidepressant use during pregnancy and the rates of spontaneous abortions; a meta-analysis. Ann Pharmacother. 2005, 39, 803-9.
69. Latendresse G, Ruiz RJ. Maternal corticotropin-releasing hormone and the use of selective serotonin reuptake inhibitors independently predict the occurrence of preterm birth. J Midwifery Womens Health. 2011, 56, 118-26.
70. Kallen, B.A.; Otterblad Olausson P. Maternal use of selective serotonin reuptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res. A. Clin Mo. Teratol. 2007, 79, 301-8.
71. Kinney, H.C.; Belliveau, R.A.; Trachtenberg, F.L.; Rava, L.A.; Paterson, D.S. The development of the medullary serotonergic system in early human life. Autonomic Neuroscience: Basic and Clinical. 2007, 132, 81-1.
72. Visser, G.H.A.; Mulder, E.J.H.; Ververs, F.F.T. Fetal behavioral teratology. J Matern Fetal Neonatal Med. 2010, 23, 14-16.
73. Maciag, D.; Simpson, K.L.; Coppinger, D.; Lu, Y.; Wang, Y.; Lin, R.C.; Paul, I.A. Neonatal antidepressant exposure has lasting effects on behaviour and serotonine circuitry. Neuropsychopharmacology. 2006, 31, 47-57.
74. Lucki, I. The spectrum of behaviors influenced by serotonin. Bio. Psychiatry. 1998, 44, 151-162.
75. Rampono, J.; Simmer, K.; Ilett, K.F.; Hackett, L.P.; Doherty, D.A.; Elliot, R.; Kok, C.H.; Coenen, A.; Forman, T. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry. 2009, 42, 95-100.
76. Nordeng, H.; Spigset, O. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant. Drug Saf., 2005, 28, 565-81.
77. Rahimi, R.; Nikfar, S.; Abdollahi, M. Pregnancy outcome following exposure to serotonin-reuptake inhibitors: a meta-analysis of clinical trials. Reprod. Toxicol., 2006, 22, 571-575.
78. Sanz, E.J.; De Las Cuevas, C.; Kiuru, A.; Bate, A.; Edwards, R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005, 365, 482-7.
79. Chambers, C.D.; Hernandez-Diaz, S.; Van Marter, L.J. Selective serotoninreuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006, 354, 579-87.
80. Oberlander, T.F.; Warburton, W.; Misri, S.; Aghajanian, J.; Hertzman, C. Effects of timing and duration of gestational exposure to serotonine reuptahe inhibitors antidepressants: population-based study. Br J Psychiatry. 2008, 192, 338-43.
81. Laine, K.; Heikkinen, T.; Ekblad, U.; Kero, P. Effects of exposure to selective serotonine reuptake inhibitors during pregnancy on serotoninergic system in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003, 60, 720-6.
82. Ververs, T.F.; van Wensen, K.; Freund, M.W.; van der Heide, M.; Visser, G.H.; Schobben, A.F.; de Jong-van den Berg, L.T.; Egberts, A.C. Association between antidepressant drug use during pregnancy and child healthcare utilisation. BJOG. 2009, 116, 1568-77.
83. Nulman, I.; Rovet, J.; Stewart, D.E.; Wolpin, J.; Gardner, H.A.; Theis, J.G.; Kulin, N.; Koren, G. Neurodevelopment of children exposed in utero to antidepressant drugs. New Eng J Med. 1997, 336, 258-62.
84. Casper, R.C.; Fleisher, B.E.; Lee-Ancajas, J.C-.; Gaylor, E.; DeBattista, A. Follow-up of children of depressed mothers exposed or not exposed to antidepressants during pregnancy. J Pediatr. 2003, 142, 402-408.
85. Nulman, I.; Rovet, J.; Stewart, D.E.; Wolpin, J.; Pace-Asciak, P.; Shuhaiber, S.; Koren, G. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective controlled study. Am J Psychiatry. 2002, 159, 1889-95.
86. Mortensen, J.T.; Olsen, J.; Larsen, H.; Bendsen, J.; Obel, C.; Sørensen, H.T. Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics. Euro. J. Epidem. 2003, 8, 769-771.
87. Misri, S.; Kendrick, K. Treatment of perinatal mood and anxiety disorders: a review. Can J Psychiatry. 2007, 52, 489-98.
88. Oberlander, T.F.; Reebye, P.; Misri, S.; Papsdorf, M.; Kim, J.; Grunau, R.E. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med. 2007, 161, 22-29.
89. Croen, L.A.; Grether, J.K.; Yoshida, C.K.; Odouli, R.; Hendrick, V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011, 68, 1104-12.
90. Bellissima, V.; Visser, G. H.A.; Ververs, T. F.; van Bel, F.; Termote J. U.M.; van der Heide, M.; Florio, P.; Li Volti, G.; Gazzolo, D. Antenatal maternal antidepressants drugs affect Activin A concentrations in maternal blood, in amniotic fluid and in fetal cord blood. J Matern Fetal Neonatal Med. 2011, 24, 31-34.
91. Michetti, F; Gazzolo, D. S100B protein in biological fluids: a tool for perinatal medicine. Clin Chem. 2002, 48, 2097-104.
92. Michetti, F.; Gazzolo, D. S100B testing in pregnancy. Clin Chim Acta. 2003, 335, 1-7.
93. Gazzolo, D.; Abella, R.; Marinoni, E.; di Iorio, R.; Li Volti, G.; Galvano, F.; Frigiola, A.; Temporini, F.; Moresco, L.; Colivicchi, M.; Sabatini, M.; Ricotti, A.; Strozzi, M.C.; Crivelli, S.; Risso, F.M.; Sannia, A.; Florio, P. New markers of neonatal neurology. J Matern Fetal Neonatal Med. 2009, 22, 57-61.
94. Gazzolo, D.; Abella, R.;, Frigiola, A.; Giamberti, A.; Tina, G.; Nigro, F.; Florio, P.; Colivicchi, M.; Temporini, F.; Ricotti, A.; Li Volti, G.; Galvano, F. Neuromarkers and unconventional biological fluids. J Matern Fetal Neonatal Med. 2010, 23, 66-9.
95. Gazzolo, D.; Kornacka, M.; Bruschettini, M.; Lituania, M.; Giovannini, L.; Serra, G.; Majewska, U.; Michetti, F. Maternal glucocorticoid supplementation and S100B protein concentrations in cord blood and urine of preterm infants. Clin Chem. 2003, 49, 1215-8.
96. Sannia, A.; Risso, F.M.; Serpero, L.D.; Frulio, R.; Michetti, F.; Abella, R.; Frigiola, A.; Giamberti, A.; Gazzolo, D. Antenatal glucocorticoid treatment affects preterm infants' S100B urine concentration in a dose-dependent manner. Clin Chim Acta. 2010, 411, 1539-41.
97. Gazzolo, D.; Bruschettini, M.; Di Iorio, R.; Marinoni, E.; Lituania, M.; Marras, M.; Sarli, R.; Bruschettini, P.L.; Michetti, F. Maternal nitric oxide supplementation decreases cord blood S100B in intrauterine growth-retarded fetuses. Clin Chem. 2002, 48, 647-50.
98. Michetti, F.; Massaro, A.; Murazio, M. The nervous system-specific S100 antigen in cerebrospinal fluid as a possible index of cell injury in the nervous system. Neurosci Lett. 1979, 11, 171-5.
99. Michetti, F.; Massaro, A.; Russo, G.; Rigon, G. The S-100 antigen in cerebrospinal fluid as a possible index of cell injury in the nervous system. J Neurol Sci.1980, 44, 259-63.
100. Gazzolo, D.; Vinesi, P.; Marinoni, E.; Di Iorio, R.; Marras, M.; Lituania, M.; Bruschettini, P.; Michetti, F. S100B protein concentrations in cord blood: correlations with gestational age in term and preterm deliveries. Clin Chem. 2000, 46, 998-1000.
101. Gazzolo, D.; Bruschettini, M.; Corvino, V; Sarli, R; Lituania, M; Bruschettini, P.L. S100B protein concentrations in amniotic fluid are correlated with gestational age and with cerebral ultrasound scanning parameters results in healthy fetuses. Clin Chem. 2001, 47, 954-6.
102. Gazzolo, D.; Lituania, M.; Bruschettini, M.; Bruschettini, P.; Michetti, F. S100B protein concentrations in amniotic fluid are higher in monoamniotic than in diamniotic twins and singleton pregnancies. Clin Chem. 2003, 49, 997-9.
103. Florio, P.; Michetti, F.; Bruschettini, M.; Lituania, M.; Bruschettini, P.; Severi, F.M.; Petraglia, F.; Gazzolo, D. Amniotic fluid S100B protein in mid-gestation and intrauterine fetal death. Lancet. 2004, 364, 270-2.
104. Gazzolo, D.; Marinoni, E.; di Iorio, R.; Lituania, M.; Bruschettini, P.L.; Michetti. F. Circulating S100beta protein is increased in intrauterine growthretarded fetuses. Pediatr Res. 2002, 51, 215-9.
105. Gazzolo, D.; Marinoni, E.; Di Iorio, R.; Lituania, M.; Marras, M.; Bruschettini, M.; Bruschettini, P.; Frulio, R.; Michetti, F.; Petraglia, F.; Florio, P. High maternal blood S100B concentrations in pregnancies complicated by intrauterine growth restriction and intraventricular hemorrhage. Clin Chem. 2006, 52, 819-26.
106. Sannia, A.; Zimmermann, L.J.; Gavilanes, A.W.; Vles, H.J.; Serpero, L.D.; Frulio, R.; Michetti, F.; Gazzolo, D. S100B Protein maternal and fetal bloodstreams gradient in healthy and small for gestational age pregnancies. Clin Chim Acta. 2011, 412, 1337-40.
107. Pawluski, J.L.; Galea, L.A.M.; Brain, U.; Papsdorf, M.; Oberlander, T.F. Neonatal S100B protein levels after prenatal exposure to selective serotonin reuptake inhibitors. Pediatrics. 2009, 124, 662-670.
108. Eriksen, J.L.; Gillespie, R.A.; Druse, M.J. Effects of in utero ethanol exposure and maternal treatment with a 5-HT(1A) agonist on S100Bcontaining glial cells. Dev Brain Res. 2000, 121, 133-143.
109. Akbari, H.M.; Whitaker-Azmitia, P.M.; Azmitia, E.C. Prenatal cocaine decreases the trophic factor S-100 beta and induced microcephaly: reversal by postnatal 5-HT1A receptor agonist. Neurosci Lett. 1994, 170, 141-144.
110. Van den Hove, D.L.; Steinbusch, H.W.; Bruschettini, M.; Gazzolo, D.; Frulio, R.; Scheepens, A.; Prickaerts, J.; Blanco, C.E. Prenatal stress reduces S100B in the neonatal rat hippocampus. Neuroreport. 2006, 17, 1077-80.
111. Tramontina, A.C.; Tramontina, F,; Bobermin, L.D.; Zanotto, C.; Souza, D.F.; Leite, M.C.; Nardin, P.; Gottfried, C.; Gonçalves, C.A. Secretion of S100B, an astrocyte-derived neurotrophic protein, is stimulated by fluoxetine via a mechanism independent of serotonin. Prog Neuropsychopharmacol Biol Psychiatry. 2008, 32, 1580-3.